Cliquez pour voir le graph
Connexions
Cliquez pour voir la ligne de temps
Ligne de temps
Projets
Publications
Télécharger-
2024Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies, Pathogens and Immunity, 2024, 10 (1), pp.1-11. ⟨10.20411/pai.v10i1.752⟩.
-
2024Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2., iScience 2024 Jul; 27(7): 110354.
-
2024Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells., Nat Commun 2024 Jan; 15(1): 178.
-
2023High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1., J Virol 2023 Dec; (): e0135123.
-
2023SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells., Nat Immunol 2023 Nov; (): .
-
2023TMPRSS2 is a functional receptor for human coronavirus HKU1., Nature 2023 Oct; (): .
-
2023HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria., Nat Commun 2023 Oct; 14(1): 6326.
-
2023Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller., Cell Host Microbe 2023 Jul; (): .
-
2023Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies., Nat Commun 2023 Feb; 14(1): 824.
-
2023Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants., iScience 2023 Feb; (): 106124.
-
+Voir la liste complète de publications